+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

US Irritable Bowel Syndrome Treatment Market to 2027 - Country Analysis and Forecasts by Type; Product; Distribution Channel

  • ID: 5017998
  • Report
  • March 2020
  • Region: United States
  • 76 pages
  • The Insight Partners
UP TO OFF
until Sep 30th 2021

FEATURED COMPANIES

  • Alfasigma S.p.A.
  • Allergan Plc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Lannett Company Inc.
  • Synthetic Biologics, Inc.
The US irritable bowel syndrome treatment market is expected to reach US$ 1,276.21 million by 2027 from US$ 586.61 million in 2019; it is anticipated to grow with a CAGR of 10.3% from 2020 to 2027.

The growth of the US irritable bowel syndrome treatment market is primarily attributed to the increasing prevalence of irritable bowel syndrome and associated conditions, and increasing numbers of FDA approvals and drug developments. However, the limitations with regard to product availability and treatment inefficiency are likely to continue to restrain the growth of market during the forecast years. Further, the increasing number of FDA approvals and drug development activities is likely to accelerate the growth of the US irritable bowel syndrome treatment market during the forecast period.

Majority of the established as well as new players are coming forward to manufacture drugs for irritable bowel syndrome, which is likely to result in the availability of a wide range of drugs in the market. For instance, in 2019, Ardelyx, Inc., got FDA approval for its Ibsrela (tenapanor) for treating the adults with irritable bowel syndrome with constipation (IBS-C). The newly approved drug is a small molecule that is minimally absorbed, which acts locally in the gastrointestinal (GI) tract to lower the abdominal pain and increase the bowel movements in IBS-C patients. Furthermore, in April 2019, SunGen Pharma received FDA approval for its Dicyclomine Hydrochloride Injection USP, 20 mg/2 mL (10 mg/mL), to treat irritable bowel syndrome. The drug help reduce stomach and intestinal cramping.

The US irritable bowel syndrome treatment market players are also projected to introduce generic drugs in the coming years. In 2020, Teva Pharmaceutical, and Israel based drug manufacturing company, received FDA approval for its very first generic version irritable bowel syndrome drug - Linzess (linaclotide). According to its estimates, the drug is likely to observe thriving sales in the US market in the coming years.

The US irritable bowel syndrome treatment market, by type, has been segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). In 2019, the IBS-M segment held the largest share of the market, and it is further expected to report the highest CAGR in the market during the forecast period. The US irritable bowel syndrome treatment market, based on the product was segmented into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. The linaclotide segment held the largest share of the market in 2019, and the segment is further estimated to register the fastest CAGR during 2020-2027. Moreover, based on distribution channel, the US irritable bowel syndrome treatment market has been segmented into hospitals pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospitals pharmacies segment held the largest share of the market in 2019. However, the market for the drug stores and retail pharmacies segment is expected to grow at the CAGR during from 2020 to 2027.

A few of the major primary and secondary sources referred to for preparing the irritable bowel syndrome treatment market report are the World Health Organization, Food and Drug Administration, American Society for Gastrointestinal Endoscopy, Centers for Disease Control and Prevention (CDC), and International Foundation for Gastrointestinal Disorders, Inc.

Reasons to Buy:
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the US Irritable Bowel Syndrome Treatment market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global hemostats market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alfasigma S.p.A.
  • Allergan Plc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Lannett Company Inc.
  • Synthetic Biologics, Inc.
1. Introduction
1.1 Study Scope
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 US Irritable Bowel Syndrome Treatment Market - ByType
1.3.2 US Irritable Bowel Syndrome Treatment Market - By Product
1.3.3 US Irritable Bowel Syndrome Treatment Market - By Distribution Channel

2. Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. US Irritable Bowel Syndrome Treatment Market Landscape
4.1 Market Overview
4.2 PEST Analysis
4.2.1 US: PEST Analysis
4.3 Expert Opinion

5. US Irritable Bowel Syndrome Treatment Market - Key Market Dynamics
5.1 Key Drivers
5.1.1 Increasing prevalence of irritable bowel syndrome and associated conditions
5.1.2 Increasing number of FDA approvals and drug developments
5.2 Key Market Restraints
5.2.1 Limited number of product availability and treatment inefficiency
5.2.2 Disruptive effect of corona virus on the US economy
5.3 Key Market Opportunities
5.3.1 Increasing disposable incomes of the population
5.4 Future Trends
5.4.1 Development of medical devices for the treatment of irritable bowel syndrome
5.5 Impact Analysis

6. Irritable Bowel Syndrome Treatment - US Market Analysis
6.1 US Irritable Bowel Syndrome Treatment Market Overview
6.2 Market Positioning of Key Players

7. US Irritable Bowel Syndrome Treatment Market Analysis - By Type
7.1 Overview
7.2 Global Irritable Bowel Syndrome Treatment Market Share by Type 2019 & 2027 (%)
7.3 Mixed IBS (IBS-M)
7.3.1 Overview
7.3.2 Mixed IBS (IBS-M) Market Revenue and Forecast to 2027 (US$ Mn)
7.4 IBS with Diarrhea (IBS-D)
7.4.1.1 IBS with Diarrhea Market Revenue and Forecast to 2027 (US$ Mn)
7.5 IBS with Constipation (IBS-C)
7.5.1.1 IBS with Constipation (IBS-C) Market Revenue and Forecast to 2027 (US$ Mn)

8. US Irritable Bowel Syndrome Treatment Market Analysis And Forecasts To 2027-Product
8.1 Overview
8.2 Global Irritable Bowel Syndrome Treatment Market Share by Product 2019 & 2027 (%)
8.3 Rifaximin
8.3.1 Overview
8.3.2 Rifaximin Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Eluxadoline
8.4.1 Overview
8.4.2 Eluxadoline Market Revenue and Forecast to 2027 (US$ Mn)
8.5 Lubiprostone
8.5.1 Overview
8.5.2 Lubiprostone Market Revenue and Forecast to 2027 (US$ Mn)
8.6 Linaclotide
8.6.1 Overview
8.6.2 Linaclotide Market Revenue and Forecast to 2027 (US$ Mn)
8.7 Others
8.7.1 Overview
8.7.2 Others Market Revenue and Forecast to 2027 (US$ Mn)

9. US Irritable Bowel Syndrome Treatment Market Analysis And Forecasts To 2027 - Distribution Channel
9.1 Overview
9.2 Global Irritable Bowel Syndrome Treatment Market Share by Distribution Channel 2019 & 2027 (%)
9.3 Hospitals Pharmacies
9.3.1 Overview
9.3.2 Hospitals Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Drug Stores and Retail Pharmacies
9.4.1 Overview
9.4.2 Drug Stores and Retail Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
9.5 Online Pharmacies
9.5.1 Overview
9.5.2 Online Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)

10. US Irritable Bowel Syndrome Treatment Market -Industry Landscape
10.1 Overview
10.2 Growth Strategies In The Irritability Bowel Syndrome Treatment Market, 2017-2019
10.3 Organic Growth Strategies
10.3.1 Overview
10.3.2 Recent Organic Developments By Players In The Irritability Bowel Syndrome Treatment Market
10.4 Inorganic Growth Strategies
10.4.1 Overview
10.4.2 Recent Inorganic Developments By Players In The Irritability Bowel Syndrome Treatment Market

11. Company Profiles
11.1 Ironwood Pharmaceuticals, Inc.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Allergan Plc.
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Sebela Pharmaceuticals, Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Takeda Pharmaceutical Company Limited
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Alfasigma S.p.A.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Astellas Pharma Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 AstraZeneca
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Synthetic Biologics, Inc.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 SWOT Analysis
11.8.5 Key Developments
11.9 Bausch Health Companies Inc.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Lannett Company Inc.
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments

12. Appendix
12.1 About the Publisher
12.2 Word Index
Note: Product cover images may vary from those shown
  • Ironwood Pharmaceuticals, Inc.
  • Allergan Plc.
  • Sebela Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Alfasigma S.p.A.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Synthetic Biologics, Inc.
  • Bausch + Lomb Incorporated
  • Lannett Company Inc.
Note: Product cover images may vary from those shown
Adroll
adroll